Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) had its price objective boosted by stock analysts at Barclays from $48.00 to $53.00 in a report issued on Friday,Benzinga reports. Get Celldex Therapeutics alerts:View Our Latest Report on CLDXCelldex Therapeutics Price PerformanceCLDX opened at $41.56 on Friday. Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last released its earnings results on Thursday, August 6th. Celldex Therapeutics Company Profile(Get Free Report)Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. See AlsoReceive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.